Though our study found the differences of potential immunotherapy effects and verify it was not merely attributed to the differences between LGGs and GBM, we must emphasize that up to now, the failures of PD-1/PD-L1 immunotherapy for glioma had been verified in phase III clinical trial (Filley et al., 2017; Zhao et al., 2019a; Reardon et al., 2020). This evidence concerns the gene CD274 and glioblastoma.